Patient
SITE014-0197
completed Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE014 (NLD) (Dr. Moreau)
consented 2026-04-24
Adverse events
7
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 7
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-01-31 (study day 89); relationship: not assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-30 (study day 88); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-13 (study day 71); relationship: not assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-01-08 (study day 66); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-14 (study day 41); relationship: not assessed
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-12-05 (study day 32); relationship: not assessed
Grade 4 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-11-17 (study day 14); relationship: not assessed; serious criteria: life-threatening
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.